Haili Bio (603718): Non-plague situation drags down performance, Mobility Insurance, and PICC to improve long-term performance space

Haili Bio (603718): Non-plague situation drags down performance, Mobility Insurance, and PICC to improve long-term performance space

The event company released its semi-annual report for 2019.

From January to June 2019, the company’s operating income was 1.

39 trillion, up 28 each year.

55%; net profit attributable to shareholders of the listed company is 0.

1.6 billion, down 51 a year.

25%.

The net profit attributable to shareholders of the listed company after deduction is zero.

1.4 billion, down 49 a year.

43%.

By quarter, 2019Q1 / Q2 company operating income is 0.

81/0.

58 ppm, with a ten-year growth rate of 31.

04% / 25.

22%; net profit attributable to mother is 0.

06/0.

09 million yuan, a ten-year growth rate of -68.

52% /-20.

13%.

Our analysis and judgments have been consolidated to increase revenue, and performance has declined due to the impact of piglets. The company’s main products include livestock and poultry vaccines, mainly pig vaccines.

Reported numbers, affected by the African swine fever epidemic, domestic pig populations have decreased significantly.

According to the data of the Ministry of Agriculture and Rural Affairs, the national live pig inventory in July 2019 decreased by 32 each year.

2%, a decrease of 9 from the previous month.

4%; the number of capable sows in stock is reduced by 31 each year.

9%, a decrease of 8 from the previous month.

9%.

Affected by this, the swine vaccine market scale has improved and shrunk. The company’s products are mainly pig vaccines, so production capacity has decreased, and profit has decreased by 51.

25%.

Revenue was continuously affected by the growth of subsidiaries Yang Ling Jinhai and Jiemen Biological28.

55%.

In the first half of 2019, Yangling Jinhai achieved revenue of 3,286.

970,000 yuan, net profit -1838.

440,000 yuan; Jiemen Biological achieved income of 4639.

920,000 yuan, net profit in 2015.

320,000 yuan.

Profitability has improved, and the company’s profitability has improved during the period when the expense ratio has dropped.

In terms of gross profit margin, the gross profit margin of the company in 2019H1 is 46.

30%, a decrease of 21 per year.

38 points.In terms of net interest rate, the company’s net interest rate for 2019H1 is 5.

30%, a decrease of 17 per year.

23pct.

In terms of expense ratio, 2019H1 company’s sales expense subsidy16.

68%, a decrease of 8 per year.

38pct, mainly due to the company’s streamlined marketing center staff structure and reduced sales refund fees; management expenses 14

52%, R & D expense ratio 11.

74%, a total decrease of 6 over the same period last year.

57 points; financial expenses 6.

1%, 0 per year.

06 points.

The company’s period expense ratio decreased by 15.

01pct.

The main business of animal health insurance continued to be strengthened, and the development of pig vaccines and poultry vaccines was synchronized with the promotion of pig vaccines. In January 2019, Yang Ling Jinhai Shi and other units jointly declared swine foot and mouth disease type O, type A bivalent inactivated vaccine (OHM / 02 strain +AKT-Baozhu) obtained a new veterinary drug certificate, and strived to obtain product approval document approval for marketing this year.

At present, the swine fever virus E2 recombinant baculovirus inactivated vaccine 淡水桑拿网 has completed review experiments and is waiting to be evaluated by the meeting; the parapig trivalent inactivated vaccine has entered the review and inspection stage; the swine pseudorabies virus type 2 gE / TK gene deletion inactivated vaccine is clinicalThe trial unit has passed the GCP and is preparing the vaccine registration announcement.

Other cooperative research and development projects as well as independently developed joint vaccines for pigs are actively carrying out laboratory research and new veterinary drug registration applications.

In terms of poultry vaccines, the company obtained a new veterinary drug certificate such as the “Avian Influenza DNA Vaccine (H5 Subtype, pH5-GD)” on May 24, 2018, and subsequently stocked the Chicken Newcastle Disease and Infectious Bronchitis Dual Live Vaccine (LaSota strain + LDT3-A strain), chicken Newcastle disease, bird flu (H9 subtype), infectious bursal disease triple inactivated vaccine (LaSota strain + S strain + VP2 protein), chicken Newcastle disease, bird flu (H9 subtype),Adenovirus disease triple inactivated vaccine (LaSota strain + SD95 strain + SDC4 strain) and other poultry vaccine products, more research and development and sales of poultry vaccines, disperse the risk of excessive proportion of swine vaccines, and maintain stable overall performance.

Advancement of the People’s Insurance Strategy to raise the long-term performance ceiling The company’s investment in June 20182.

The US $ 9.8 billion completed the wholly-owned acquisition of Shortcut Bio, which is the core raw material for external diagnostic reagents. The global industry scale is about 35 billion, and the prospects are bright.

In the first half of 2019, Jiemen Biological developed rapidly and achieved revenue of 4,639.

920,000 yuan, net profit in 2015.

320,000 yuan, initially expected to exceed 36 million performance commitments.

In July 2018, the company set up a joint venture with WuXi Biological, which is mainly engaged in the CDMO (custom contract R & D and production) business of human vaccines (including cancer vaccines). The company invested 1.

500 million, holding 30%.

On May 20, 2019, WuXi Biologics, a subsidiary of WuXi Biologics, and the global vaccine giant successfully signed a letter of intent for long-term production cooperation and reached a strategic partnership.

The initial 20-year production contract is expected to exceed US $ 3 billion. In order to reach this agreement, WuXi Invest invested in the establishment of Hong Kong WuXi Hyde’s proposed new Chiji vaccine stock solution (DS) and preparation (DP) production and quality control (QC).The laboratory is an integrated production base, which specializes in producing an innovative vaccine product of the global vaccine giant and supplying it to the global market.

On August 29, 2019, the company changed and adopted the “Timetable for Investing in WuXi Hyde Hong Kong Co., Ltd.”, invested US $ 42 million through transfer and capital increase, and obtained 30% of Hong Kong WuXi Hyde’s shares.With the launch of CDMO cooperation for more human vaccines, the company will obtain new growth points in performance.

Investment suggestion: We expect the company’s operating income to be 2 in 2019-2020.

8 billion, 3.

08 million yuan, an increase of 9 in ten years.

80% and 10.

11%; net profit attributable to mothers is 0.

380,000 yuan, 0.

48 ppm, an 83-year increase.

16%, 24.

60%; the company’s current total market value is 8.4 billion, corresponding to PE of 218.

4x and 175.

3x, maintain the company’s “Neutral” rating.

Risk warning: industry competition intensifies; the swine fever epidemic affects the industry inventory to continue to deteriorate.

Related Articles

Traditional Chinese medicine for lowering blood pressure

Traditional Chinese medicine for lowering blood pressure Uncaria: hooked branches of Rubiaceae. Sweet and slightly cold. It has the functions of clearing heat, calming the liver and quenching the fever, and soothing the breath. The stalks of Uncaria contains a variety of dioxazole alkaloids, including Unococline, Isorhynchophylline, Total Uncaria, and non-alkaloid. The major effective antihypertensive […]
Read more

[Can I eat pears with high blood sugar]_High blood sugar

銆愯绯栭珮鍙互鍚冩ⅷ鍚椼€慱琛€绯栭珮 鐩镐俊寰堝浜洪兘鍠滄鍚冩ⅷ瀛愬惂锛屽洜涓烘灉鑲夐矞缇庯紝鑰屼笖鑲夎剢澶氭眮閰哥敎鍙彛锛岃€屼笖鍚湁绯栬泲鐧借川锛岃剛鑲⒊姘村寲鐗╃瓑杩欎簺钀ュ吇鐗╄川锛屽鍋ュ悍姣旇緝鏈夊埄锛岀硸灏跨梾浜轰篃鍙互椋熺敤銆?1 銆 佹 ⅷ 揈 柞 矞 Tui 庯 庎 営 澶?姹侊紝閰哥敎鍙彛锛岄鍛宠姵棣欎紭缇庛€傚瘜鍚硸銆佽泲鐧借川銆佽剛鑲€佺⒊姘村寲鍚堢墿鍙婂绉嶇淮鐢熺礌锛屽浜轰綋鍋ュ悍鏈夐噸瑕佷綔鐢ㄣ€傛ⅷ瀛愬叿鏈夋竻鑲哄吇鑲虹殑浣滅敤銆傚鍚冩ⅷ鐨勪汉杩滄瘮涓嶅悆鎴栧皯鍚冩ⅷ鐨勪汉鎰熷啋鏈虹巼瑕佷綆锛屾墍浠ユ湁绉戝瀹跺拰鍖诲笀鎶婃ⅷ绉颁负鈥滃叏鏂逛綅鐨勫仴搴锋按鏋溾€濇垨鈥滃叏绉戝尰鐢熲€濄€?2 銆 佺 敱 浜 庣 ぞ 浼 ニ 偂 偞 ン ┖ 姘 旀 Thin 镆 撴 瘮 碎 幧 弗 幏 纴 庴 姐 ㄥ 彲 鏀 叀 幤 幤 幹 峾 峾 峾 峤 峾 峤勫姛鏁堬紝鍙互闄嶄綆鑲洪儴鍙楃┖姘斾腑鐨勭伆灏樺拰鐑熷皹鐨勫奖鍝嶃€傛ⅷ鏋滆繕鍙互鍔犲伐鍒朵綔姊ㄥ共銆佹ⅷ鑴€佹ⅷ鑶忋€佹ⅷ姹併€佹ⅷ缃愬ご绛夛紝涔熷彲鐢ㄦ潵閰块厭銆佸埗閱嬨€傛ⅷ鏋滆繕鏈夊尰鐢ㄤ环鍊硷紝鍙姪娑堝寲銆佹鼎鑲烘竻蹇冿紝娑堢棸姝㈠挸銆侀€€鐑€佽В姣掔柈鐨勫姛鏁堬紝杩樻湁鍒╁翱銆 佹 鼎 渚 擑 […]
Read more

[Difference between Hangbai Chrysanthemum and Fetal Chrysanthemum]

[Difference between Hangbai Chrysanthemum and Fetal Chrysanthemum] Hangbai chrysanthemum and fetal chrysanthemum are actually different. The main differences can be expressed in different aspects. For example, the shape of the chrysanthemum also has effects.Qingrejiedu, Pinggan eyesight effect. The first difference: the shape of the chrysanthemum: the chrysanthemum is a bud of a chrysanthemum, also known […]
Read more
Search for: